London, 7 August 2024 - Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and Participant Engagement. The position has been created to support Richmond’s strategic ambitions and communications and its commitment to enhancing engagement with participants in its clinical trials.

Liz joined Richmond Pharmacology over two years ago as Head of Marketing and has since made significant contributions to the company. Her innovative approach, vision, and commitment to excellence have been instrumental in strengthening Richmond’s communication and marketing efforts and among her many achievements has been her recent delivery of a complete company rebrand.

In this new role, Liz will continue to lead and oversee all aspects of Richmond’s communication and marketing strategies. In addition, Liz will manage the teams dedicated to attracting, enrolling, and retaining participants for clinical studies – critical to the success and feasibility of Richmond’s trials. - while technical oversight is provided by the company’s co-founders Dr Jorg Taubel and Dr Ulrike Lorch.

Prior to joining Richmond, Liz has had a broad marketing experience spanning over 20 years, including working in a variety of industries from financial services and a not-for-profit leisure trust to engineering and construction and hospitality and tourism.

Liz commented on her new role: "I am deeply honoured to take on the role of Director of Communications and Participant Engagement at Richmond Pharmacology. Over the past two years, I have witnessed firsthand the dedication and innovation that drives our team. I am excited to continue working closely with our participants and to further enhance our communication strategies, ensuring that Richmond remains at the forefront of clinical trial excellence. Our participants are central to everything we do, and I look forward to leading efforts to engage, support, and retain them throughout their journey with us."

Latest news

Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

First patient enrolled in telehealth study, the Pathway Study

February 25, 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event